nevirapine has been researched along with Tuberculosis, Drug-Resistant in 3 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we aimed to quantify nevirapine and LPV/r drug-drug interaction effects on bedaquiline and M2 in patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) using population pharmacokinetic (PK) analysis and compare these with model-based predictions from single-dose studies in subjects without TB." | 1.46 | Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. ( Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM, 2017) |
| "Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4." | 1.43 | Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. ( Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Daftary, A | 1 |
| Orrell, C | 1 |
| Dooley, KE | 1 |
| Rivet Amico, K | 1 |
| Friedland, G | 1 |
| Pandie, M | 2 |
| Wiesner, L | 1 |
| McIlleron, H | 1 |
| Hughes, J | 1 |
| Siwendu, S | 1 |
| Conradie, F | 1 |
| Variava, E | 1 |
| Maartens, G | 2 |
| Brill, MJ | 1 |
| Svensson, EM | 1 |
| Karlsson, MO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for nevirapine and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Substitution; Fem | 2019 |
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitorin | 2016 |
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines | 2017 |